In 2023, Luye Pharma Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, Luye Pharma Group has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
In 2023, the total operational greenhouse gas (GHG) emissions of Luye Pharma Group amounted to 76,201.353 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Luye Pharma Group decreased by 2.41%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
In 2023, the total Scope 1 emissions of Luye Pharma Group were 10,755.273 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Compared to the previous year (2022), Luye Pharma Group's Scope 1 emissions remained relatively stable, indicating that Luye Pharma Group's emissions have plateaued with no significant change in its operational footprint.
In 2023, Luye Pharma Group reported Scope 2 greenhouse gas (GHG) emissions of 65,446.08 tCOâ‚‚e without specifying the calculation method.
Compared to the previous year (2022), Luye Pharma Group's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Luye Pharma Group 's emissions have plateaued with no significant change in its energy consumption footprint.
In 2023, Luye Pharma Group reported its Scope 2 emissions using an unspecified methodology.